Cannabis companies should be taking advantage of the mania to raise money.
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
After recent weakness in the biotech sector, here are some names to start watching.
The answer is plenty, but you can't trade that.
Merck shares retreat as regulatory approval ramps up speculation.
While markets are higher Tuesday, there is little to suggest recent choppy action won't continue.
It is all about perception, and here are strong names to pick up on market weakness.
A week of bad news for Ride Aid may be good news for its competitors Walgreens and CVS.
An updated strategy for the high-flying REGN.
It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.

Columnist Conversations

Amazon (AMZN) has the 20 DMA @ 1958 above. It can certain trade lower as it has made lower weekly highs and lo...
Tilray's staggering 41% rise this morning leaves the company with an insane valuation and leaves Canopy Growth...
I badly want to be the person that calls the top in red-hot cannabis stocks, but fear looking like a short-ter...
Now the government will get to really dive into the inner workings of Tesla (TSLA) . Who knows what else they...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.